We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $1.8B
1-Year Est. Return 36.16%
This Fund
S&P 500
This Quarter Est. Return
+15.94%
1 Year Est. Return
+36.16%
3 Year Est. Return
+116.66%
5 Year Est. Return
+140.56%
10 Year Est. Return
+771.9%
AUM
$1.73B
AUM Growth
+$152M
Cap. Flow
-$38.6M
Cap. Flow %
-2.23%
Top 10 Hldgs %
25.39%
Holding
270
New
10
Increased
28
Reduced
188
Closed
10

Sector Composition

Rank Sector Weight
1 Healthcare 30.1%
2 Technology 23.78%
3 Industrials 19.76%
4 Consumer Discretionary 6.36%
5 Communication Services 6.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DFIN icon
1
Donnelley Financial Solutions
DFIN
$1.21B
$59.2M 3.43%
948,466
-53,113
-5% -$3.03M
LRN icon
2
Stride
LRN
$3.48B
$56.2M 3.26%
946,812
-179,630
-16% -$9.83M
WNS
3
DELISTED
WNS Holdings
WNS
$46M 2.67%
728,473
+4,280
+0.6% +$261K
ACIW icon
4
ACI Worldwide
ACIW
$5.81B
$44.8M 2.59%
1,463,645
-6,503
-0.4% -$163K
DOOR
5
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
$41M 2.38%
484,746
-1,408
-0.3% -$122K
PBH icon
6
Prestige Consumer Healthcare
PBH
$2.35B
$40.8M 2.36%
666,613
+112,423
+20% +$6.68M
EEFT icon
7
Euronet Worldwide
EEFT
$2.77B
$39.6M 2.3%
390,652
-6,797
-2% -$580K
MEDP icon
8
Medpace
MEDP
$16B
$39.1M 2.27%
127,640
-4,447
-3% -$1.2M
TKO icon
9
TKO Group
TKO
$13.5B
$36.8M 2.13%
450,584
+954
+0.2% +$75.7K
PCRX icon
10
Pacira BioSciences
PCRX
$1.04B
$35M 2.02%
1,035,969
+67,484
+7% +$1.97M
ARLO icon
11
Arlo Technologies
ARLO
$1.59B
$34.6M 2.01%
3,639,547
+53,607
+1% +$490K
AGM icon
12
Federal Agricultural Mortgage
AGM
$2.38B
$31.2M 1.81%
163,176
-8,856
-5% -$1.44M
ZD icon
13
Ziff Davis
ZD
$1.92B
$28.8M 1.67%
428,477
-4,312
-1% -$273K
XPO icon
14
XPO
XPO
$23.6B
$26.5M 1.53%
302,087
-1,452
-0.5% -$118K
PGTI
15
DELISTED
PGT, Inc.
PGTI
$25.4M 1.47%
623,352
-7,862
-1% -$256K
AX icon
16
Axos Financial
AX
$5.69B
$25M 1.45%
457,692
-142,130
-24% -$5.93M
AWI icon
17
Armstrong World Industries
AWI
$7.31B
$23.5M 1.36%
239,400
-1,137
-0.5% -$94K
FC icon
18
Franklin Covey
FC
$236M
$23.2M 1.35%
533,836
+24,138
+5% +$956K
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.35B
$21.7M 1.26%
692,852
-3,213
-0.5% -$76.7K
ASND icon
20
Ascendis Pharma A/S
ASND
$16.1B
$21.3M 1.23%
168,883
-904
-0.5% -$90.1K
DOCS icon
21
Doximity
DOCS
$3.75B
$20.9M 1.21%
744,018
-13,268
-2% -$313K
LGND icon
22
Ligand Pharmaceuticals
LGND
$5.84B
$19.7M 1.14%
276,008
-6,953
-2% -$410K
ESTA icon
23
Establishment Labs
ESTA
$2.72B
$19.4M 1.13%
750,909
+382,502
+104% +$11.2M
NGVT icon
24
Ingevity
NGVT
$2.48B
$18.7M 1.08%
396,066
-13,967
-3% -$580K
OZK icon
25
Bank OZK
OZK
$5.56B
$17.9M 1.04%
359,636
-2,927
-0.8% -$121K

Similar funds

Rice Hall James & Associates's Q4 2023 Portfolio in Review

As of Q4 2023, Rice Hall James & Associates held 270 positions worth $1.73B, up 9.7% from $1.57B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rice Hall James & Associates's Q4 2023 filing shows 10 new, 28 increased, 188 reduced and 10 closed positions. Its largest new stake was Addus HomeCare: 40,418 shares worth $3.75M. The largest sale was Bed Bath & Beyond, an estimated $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 28% a quarter earlier, followed by Technology and Industrials.

  • Rice Hall James & Associates's largest Q4 2023 buy was Addus HomeCare: 40,418 shares worth $3.75M.
  • Rice Hall James & Associates added most to Establishment Labs in Q4 2023, an estimated $11.2M increase.
  • Rice Hall James & Associates's biggest Q4 2023 reduction was Bed Bath & Beyond, cutting an estimated $11.2M.
  • Rice Hall James & Associates fully exited NextGen Healthcare, Inc. Common Stock in Q4 2023, selling an estimated $9.14M.
  • Rice Hall James & Associates's ten largest holdings make up 25% of its $1.73B portfolio in Q4 2023.
  • Rice Hall James & Associates opened 10 new positions and closed 10 in Q4 2023.
  • Rice Hall James & Associates's portfolio value rose 9.7% quarter-over-quarter to $1.73B.

Based on Rice Hall James & Associates's 13F filing for Q4 2023, filed 9 Feb 2024.